- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Glenmark Pharmaceuticals Ltd (GLEN)Glenmark Pharmaceuticals Ltd stock price live, this page displays NS GLEN stock exchange data. View the GLEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Glenmark Pharmaceuticals Ltd real time stock price chart below.
What Is the Glenmark Pharmaceuticals Ltd Stock Price Today?
The Glenmark Pharmaceuticals Ltd stock price today is 1,544.80.
What Is the Stock Symbol for Glenmark Pharmaceuticals Ltd?
The stock symbol for Glenmark Pharmaceuticals Ltd is "GLEN."
What Stock Exchange Does Glenmark Pharmaceuticals Ltd Trade On?
Glenmark Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Glenmark Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Glenmark Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLEN quote. (ISIN: INE935A01035)
What Is the Glenmark Pharmaceuticals Ltd Stock Price Today?
The Glenmark Pharmaceuticals Ltd stock price today is 1,544.80.
What Is the Stock Symbol for Glenmark Pharmaceuticals Ltd?
The stock symbol for Glenmark Pharmaceuticals Ltd is "GLEN."
What Stock Exchange Does Glenmark Pharmaceuticals Ltd Trade On?
Glenmark Pharmaceuticals Ltd is listed and trades on the NSE stock exchange.
Is Glenmark Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Glenmark Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLEN quote. (ISIN: INE935A01035)
1,544.80
-2.95(-0.19%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,513.40
1,552.00
52 wk Range
766.65
1,830.05
GLEN Scorecard
Full Analysis
High shareholder yield
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,513.401,552.00
52 wk Range
766.651,830.05
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(0.16%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(0.16%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockGLEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
1,608.07
Upside
+4.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Glenmark Pharmaceuticals Ltd Company Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company’s pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Compare GLEN to Peers and Sector
Metrics to compare | GLEN | Peers Peers - average of corresponding metrics from companies closely matching GLEN: MOREPENLAB, LUPIN, EMCURE, MANKIND, ABBOTINDIA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLENPeersSector |
|---|---|---|---|---|
P/E Ratio | −42.7x | 39.3x | −0.7x | |
PEG Ratio | 0.05 | 1.60 | 0.00 | |
Price/Book | 5.2x | 6.4x | 2.6x | |
Price / LTM Sales | 3.3x | 7.8x | 3.2x | |
Upside (Analyst Target) | 9.2% | 9.3% | 45.9% | |
Fair Value Upside | Unlock | −16.2% | 7.6% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -31.01
Dividend Yield
0.16%
Industry Median 0.71%
Annualised payout
2.5000
Paid annually
5-Years Growth
-
Growth Streak
FAQ
What Is the Glenmark Pharma (GLEN) Stock Price Today?
The Glenmark Pharma stock price today is 1,544.80.
What Stock Exchange Does Glenmark Pharma Trade On?
Glenmark Pharma is listed and trades on the BSE stock exchange.
What Is the Stock Symbol for Glenmark Pharma?
The stock symbol for Glenmark Pharma is "GLEN."
Does Glenmark Pharma Pay Dividends? What’s The Current Dividend Yield?
The Glenmark Pharmaceuticals Ltd dividend yield is 0.16%.
What Is the Glenmark Pharma Market Cap?
As of today, Glenmark Pharma market cap is 435.88B.
What is Glenmark Pharma Earnings Per Share?
The Glenmark Pharma EPS is -31.01.
What Is the Next Glenmark Pharma Earnings Date?
Glenmark Pharma will release its next earnings report on 12 Feb 2025.
From a Technical Analysis Perspective, Is GLEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.